CervoMed Inc
CRVO
Company Profile
Business description
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Contact
20 Park Plaza
Suite 424
BostonMA02116
USAT: +1 617 744-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Magellan merger modestly dilutive
Our view on how shareholders should respond to the Magellan merger.
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,847.70 | 14.20 | 0.16% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,527.63 | 203.29 | -0.86% |
| Dow JONES (US) | 46,597.62 | 395.64 | -0.84% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 26,025.42 | 156.88 | 0.61% |
| NASDAQ | 22,332.15 | 147.38 | -0.66% |
| Nikkei 225 | 55,239.40 | 1,539.01 | 2.87% |
| NZX 50 Index | 13,315.60 | 133.37 | 1.01% |
| S&P 500 | 6,677.50 | 38.59 | -0.57% |
| S&P/ASX 200 | 8,640.60 | 14.40 | 0.17% |
| SSE Composite Index | 4,062.98 | 13.08 | 0.32% |